… This multicenter, phase 3 trial investigates whether the incorporation of concurrent paclitaxel
and cisplatin together with a reduced total dose of radiotherapy is superior to standard …

… (area under the curve = 6 on day 1) and nab-paclitaxel (100 mg/m 2 on days 1 and 8) … -paclitaxel
in a cohort dose escalation Phase I design with 5-fluorouracil 500 mg/m 2 , hydroxyurea …

… fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB…
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced …

… paclitaxel based CCRT in locally advanced SCCHN [30,31]. Paclitaxel is tolerated with
radiotherapy … The radiation-sensitizing properties of both paclitaxel and carboplatin, as well as …

… the addition of paclitaxel to cisplatin-based concurrent chemoradiotherapy (C-CRT) for the
treatment of locally advanced carcinoma of the uterine cervix in terms of local control, disease …

… Survival rates for the patients of both cisplatin regimens (67% and 66%, respectively)
were better than the rate in the hydroxyurea group (39%) local failure rates were significantly …

… with other chemotherapeutic agents such hydroxyurea, showed superior results in cisplatin
… -FU versus weekly paclitaxel with concurrent radiotherapy showed no statistically significant …

… patients presenting with locally advanced CC. [4] Pelvic … with CCRT (hydroxyurea) and
CCRT (cisplatin + paclitaxel) were … (cisplatin + FU + hydroxyurea) was relatively higher than the …

… agents in radiotherapy, eg cisplatin and 5-fluorouracil (5-FU), … Hydroxyurea inhibits
ribonucleotide reductase and prevents … mucosal toxicity by concurrent 5-FU and paclitaxel. Late …

… , 5-Fluorouracil (5FU), and Paclitaxel. The main objective was to study the efficacy of
concurrent chemoradiotherapy in … Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to …